Reflections on the Scope and the Future of Metabolic Engineering and Its Connections to Functional Genomics and Drug Discovery

2001 ◽  
Vol 3 (2) ◽  
pp. 111-114 ◽  
Author(s):  
James E. Bailey
Keyword(s):  
Metabolic Engineering ◽  
Drug Discovery ◽  
Functional Genomics ◽  
The Future

scholarly journals Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity

Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1015
Author(s):  
Utsa Bhaduri ◽  
Giuseppe Merla
Keyword(s):  
Drug Discovery ◽  
Protein Degradation ◽  
Ubiquitin Ligase ◽  
Genetic Disorders ◽  
E3 Ubiquitin Ligase ◽  
Ubiquitin Ligases ◽  
E3 Ubiquitin Ligases ◽  
Post Translational Modification ◽  
Disease Biology ◽  
The Future

Ubiquitination is a post-translational modification that has pivotal roles in protein degradation and diversified cellular processes, and for more than two decades it has been a subject of interest in the biotech or biopharmaceutical industry. Tripartite motif (TRIM) family proteins are known to have proven E3 ubiquitin ligase activities and are involved in a multitude of cellular and physiological events and pathophysiological conditions ranging from cancers to rare genetic disorders. Although in recent years many kinds of E3 ubiquitin ligases have emerged as the preferred choices of big pharma and biotech startups in the context of protein degradation and disease biology, from a surface overview it appears that TRIM E3 ubiquitin ligases are not very well recognized yet in the realm of drug discovery. This article will review some of the blockbuster scientific discoveries and technological innovations from the world of ubiquitination and E3 ubiquitin ligases that have impacted the biopharma community, from biotech colossuses to startups, and will attempt to evaluate the future of TRIM family proteins in the province of E3 ubiquitin ligase-based drug discovery.

Metabolic engineering for drug discovery and development

2003 ◽  
Vol 2 (12) ◽  
pp. 1019-1025 ◽  
Author(s):  
Chaitan Khosla ◽  
Jay D. Keasling
Keyword(s):  
Metabolic Engineering ◽  
Drug Discovery ◽  
Drug Discovery And Development

Functional genomics, challenges and perspectives for the future

2013 ◽  
Vol 148 (3) ◽  
pp. 317-321 ◽  
Author(s):  
Ron Mittler ◽  
Vladimir Shulaev
Keyword(s):  
Functional Genomics ◽  
The Future

Drug Discovery

2018 ◽  
pp. 399-404
Author(s):  
S. Nassir Ghaemi
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
New Approach ◽  
The Past ◽  
Scientific Exploration ◽  
Clinical Indications ◽  
The Future ◽  
Clinical Diagnoses

Newer and better medications are obtained as part of the drug discovery process, which occurs mainly in the pharmaceutical industry. This process is hampered by excessive attention to marketing demands, as opposed to scientific exploration. It also is impaired by the psychiatric profession’s mistaken ideologies, whether psychoanalytic orthodoxy in the past or DSM beliefs of the present. Wrong clinical phenotypes impair finding new pharmacological mechanisms and targeting them well to the write clinical indications. Perhaps as a consequence, no treatments have been developed in the last few decades, since DSM-III, that are more effective than prior agents. Progress for the future in drug discovery will require not just better neurobiological work, but also a new approach to clinical diagnoses in psychiatry.

Sign in / Sign up

Export Citation Format

Share Document